OBJECTIVES: Prior to antiretroviral treatment, HIV-infected children frequently developed encephalopathy, resulting in debilitating morbidity and mortality. This is the first large study to evaluate the impact of HAART and central nervous system (CNS)-penetrating antiretroviral regimens on the incidence of HIV encephalopathy and survival after diagnosis of HIV encephalopathy among perinatally infected children. DESIGN: A total of 2398 perinatally HIV-infected children with at least one neurological examination were followed in a US-based prospective cohort study conducted from 1993 to 2007. METHODS: Trends in incidence rates over calendar time were described and Cox regression models were used to estimate the effects of time-varying HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy and on survival after diagnosis of HIV encephalopathy. RESULTS: During a median of 6.4 years of follow-up, 77 incident cases of HIV encephalopathy occurred [incidence rate 5.1 cases per 1000 person-years, 95% confidence interval (CI) 4.0-6.3]. A 10-fold decline in incidence was observed beginning in 1996, followed by a stable incidence rate after 2002. HAART regimens were associated with a 50% decrease (95% CI 14-71%) in the incidence of HIV encephalopathy compared with non-HAART regimens. High CNS-penetrating regimens were associated with a substantial survival benefit (74% reduction in the risk of death, 95% CI 39-89%) after HIV encephalopathy diagnosis compared with low CNS-penetrating regimens. CONCLUSION: A dramatic decrease in the incidence of HIV encephalopathy occurred after the introduction of HAART. The use of HAART was highly effective in reducing the incidence of HIV encephalopathy among perinatally infected children and adolescents. Effective CNS-penetrating antiretroviral regimens are important in affecting survival after diagnosis of HIV encephalopathy. 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
OBJECTIVES: Prior to antiretroviral treatment, HIV-infectedchildren frequently developed encephalopathy, resulting in debilitating morbidity and mortality. This is the first large study to evaluate the impact of HAART and central nervous system (CNS)-penetrating antiretroviral regimens on the incidence of HIV encephalopathy and survival after diagnosis of HIV encephalopathy among perinatally infected children. DESIGN: A total of 2398 perinatally HIV-infectedchildren with at least one neurological examination were followed in a US-based prospective cohort study conducted from 1993 to 2007. METHODS: Trends in incidence rates over calendar time were described and Cox regression models were used to estimate the effects of time-varying HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy and on survival after diagnosis of HIV encephalopathy. RESULTS: During a median of 6.4 years of follow-up, 77 incident cases of HIV encephalopathy occurred [incidence rate 5.1 cases per 1000 person-years, 95% confidence interval (CI) 4.0-6.3]. A 10-fold decline in incidence was observed beginning in 1996, followed by a stable incidence rate after 2002. HAART regimens were associated with a 50% decrease (95% CI 14-71%) in the incidence of HIV encephalopathy compared with non-HAART regimens. High CNS-penetrating regimens were associated with a substantial survival benefit (74% reduction in the risk of death, 95% CI 39-89%) after HIV encephalopathy diagnosis compared with low CNS-penetrating regimens. CONCLUSION: A dramatic decrease in the incidence of HIV encephalopathy occurred after the introduction of HAART. The use of HAART was highly effective in reducing the incidence of HIV encephalopathy among perinatally infected children and adolescents. Effective CNS-penetrating antiretroviral regimens are important in affecting survival after diagnosis of HIV encephalopathy. 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
Authors: L G Epstein; L R Sharer; J M Oleske; E M Connor; J Goudsmit; L Bagdon; M Robert-Guroff; M R Koenigsberger Journal: Pediatrics Date: 1986-10 Impact factor: 7.124
Authors: A L Belman; M H Ultmann; D Horoupian; B Novick; A J Spiro; A Rubinstein; D Kurtzberg; B Cone-Wesson Journal: Ann Neurol Date: 1985-11 Impact factor: 10.422
Authors: Andrea De Luca; B C Ciancio; D Larussa; R Murri; A Cingolani; M G Rizzo; M L Giancola; A Ammassari; L Ortona Journal: Neurology Date: 2002-08-13 Impact factor: 9.910
Authors: Cynthia McCoig; Maria Mercedes Castrejón; Elizabeth Castaño; Onix De Suman; Carmen Báez; Wilfrido Redondo; Daniel McClernon; Susan Danehower; E Randall Lanier; Carol Richardson; Amy Keller; Seth Hetherington; Xavier Sáez-Llorens; Octavio Ramilo Journal: J Pediatr Date: 2002-07 Impact factor: 4.406
Authors: Silvia Sánchez-Ramón; Salvador Resino; José M Bellón Cano; José T Ramos; Dolores Gurbindo; Angeles Muñoz-Fernández Journal: Pediatr Neurol Date: 2003-09 Impact factor: 3.372
Authors: Patricia A Garvie; Bret Zeldow; Kathleen Malee; Sharon L Nichols; Renee A Smith; Megan L Wilkins; Paige L Williams Journal: Pediatr Infect Dis J Date: 2014-09 Impact factor: 2.129
Authors: Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong Journal: Clin Infect Dis Date: 2012-02-04 Impact factor: 9.079
Authors: Paul J Pistell; Sunita Gupta; Alecia G Knight; Michelle Domingue; Romina M Uranga; Donald K Ingram; Indu Kheterpal; Carmen Ruiz; Jeffrey N Keller; Annadora J Bruce-Keller Journal: Antiviral Res Date: 2010-10-21 Impact factor: 5.970
Authors: R Nagarajan; M K Sarma; M A Thomas; L Chang; U Natha; M Wright; J Hayes; K Nielsen-Saines; D E Michalik; J Deville; J A Church; K Mason; T Critton-Mastandrea; S Nazarian; J Jing; M A Keller Journal: J Neuroimmune Pharmacol Date: 2012-10-13 Impact factor: 4.147